Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV : The Need for Specific Data
© 2021. The Author(s)..
The HIV pandemic has led to close to 40 million people living with HIV (PLWH) worldwide. To date, SARS-CoV2 has affected > 220 million people, and unprecedented global efforts have resulted in almost 6000 million doses of SARS-CoV2 vaccines being administered. Although several specific COVID-19 antiviral and anti-inflammatory treatments and SARS-CoV2 vaccines have been approved, the data available to support their use in specific populations such as PLWH remain limited. PLWH includes a range of individuals from practically unaffected immunity to severely immunocompromised individuals, and preventive and therapeutic interventions should be tailored for these subgroups . However, in most randomized clinical trials regarding antivirals, immunomodulators and vaccines for COVID-19, PLWH have been excluded or only enrolled in small numbers leading to a paucity of data. We briefly discuss the current evidence for prevention and treatment of COVID-19 in PLWH and identify key areas where more information is required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 11(2022), 1 vom: 28. Feb., Seite 1-13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Díaz, Natalia A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 31.03.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-021-00547-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332479129 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332479129 | ||
| 003 | DE-627 | ||
| 005 | 20231225215645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-021-00547-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332479129 | ||
| 035 | |a (NLM)34709579 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Díaz, Natalia A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV |b The Need for Specific Data |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a The HIV pandemic has led to close to 40 million people living with HIV (PLWH) worldwide. To date, SARS-CoV2 has affected > 220 million people, and unprecedented global efforts have resulted in almost 6000 million doses of SARS-CoV2 vaccines being administered. Although several specific COVID-19 antiviral and anti-inflammatory treatments and SARS-CoV2 vaccines have been approved, the data available to support their use in specific populations such as PLWH remain limited. PLWH includes a range of individuals from practically unaffected immunity to severely immunocompromised individuals, and preventive and therapeutic interventions should be tailored for these subgroups . However, in most randomized clinical trials regarding antivirals, immunomodulators and vaccines for COVID-19, PLWH have been excluded or only enrolled in small numbers leading to a paucity of data. We briefly discuss the current evidence for prevention and treatment of COVID-19 in PLWH and identify key areas where more information is required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a HIV infection | |
| 650 | 4 | |a PLWH | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a SARS-CoV2 vaccines | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a de Miguel, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Agüero, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Sued, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Arribas, José R |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrosioni, Juan |e verfasserin |4 aut | |
| 700 | 0 | |a Hospital Clinic COVID-19 in HIV Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrosioni, Juan |e investigator |4 oth | |
| 700 | 1 | |a Blanco, José L |e investigator |4 oth | |
| 700 | 1 | |a de la Mora, Lorena |e investigator |4 oth | |
| 700 | 1 | |a García-Alcaide, Felipe |e investigator |4 oth | |
| 700 | 1 | |a González-Cordón, Ana |e investigator |4 oth | |
| 700 | 1 | |a Inciarte, Alexis |e investigator |4 oth | |
| 700 | 1 | |a Laguno, Montserrat |e investigator |4 oth | |
| 700 | 1 | |a Leal, Lorna |e investigator |4 oth | |
| 700 | 1 | |a Martínez-Chamorro, Esteban |e investigator |4 oth | |
| 700 | 1 | |a Martínez-Rebollar, María |e investigator |4 oth | |
| 700 | 1 | |a Miró, José M |e investigator |4 oth | |
| 700 | 1 | |a Rojas, Jhon F |e investigator |4 oth | |
| 700 | 1 | |a Torres, Berta |e investigator |4 oth | |
| 700 | 1 | |a Mallolas, Josep |e investigator |4 oth | |
| 700 | 1 | |a Albiac, Laia |e investigator |4 oth | |
| 700 | 1 | |a Agüero, Daiana L |e investigator |4 oth | |
| 700 | 1 | |a Bodro, Marta |e investigator |4 oth | |
| 700 | 1 | |a Cardozo, Celia |e investigator |4 oth | |
| 700 | 1 | |a Chumbita, Mariana |e investigator |4 oth | |
| 700 | 1 | |a García, Nicol |e investigator |4 oth | |
| 700 | 1 | |a García-Vidal, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Meneses, Marta M |e investigator |4 oth | |
| 700 | 1 | |a Herrera, Sabina |e investigator |4 oth | |
| 700 | 1 | |a Linares, Laura |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Morata, Laura |e investigator |4 oth | |
| 700 | 1 | |a Martínez-Martínez, Jose A |e investigator |4 oth | |
| 700 | 1 | |a Puerta, Pedro |e investigator |4 oth | |
| 700 | 1 | |a Rico, Verónica |e investigator |4 oth | |
| 700 | 1 | |a Soriano, Alex |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Mikel |e investigator |4 oth | |
| 700 | 1 | |a Del Mar Mosquera, María |e investigator |4 oth | |
| 700 | 1 | |a Marcos, María A |e investigator |4 oth | |
| 700 | 1 | |a Vila, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Tuset, Montse |e investigator |4 oth | |
| 700 | 1 | |a Soy, Dolors |e investigator |4 oth | |
| 700 | 1 | |a Vilella, Anna |e investigator |4 oth | |
| 700 | 1 | |a Almuedo, Alex |e investigator |4 oth | |
| 700 | 1 | |a Pinazo, María J |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, José |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 11(2022), 1 vom: 28. Feb., Seite 1-13 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:1 |g day:28 |g month:02 |g pages:1-13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-021-00547-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 1 |b 28 |c 02 |h 1-13 | ||